U.S.-based biopharmaceutical company NeoImmuneTech’s CEO Yang Se-hwan speaks during the firm’s IPO press conference held at the Conrad Seoul on Yeouido in the capital, Monday. Founded in 2014, the T-cell-focused company is dedicated to the discovery of novel immune-therapeutics in cooperation with major global pharmaceutical companies. The firm’s stock allotment subscription period is for two days in early May and it’s expected to make its KOSDAQ debut in mid-March. Courtesy of NeoImmuneTech

Source link